Pleural Mesothelioma

Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma (TALAMESO)

Primary Outcome Measures Non-progression proportion [ Time Frame: 6 month after starting talazoparib ] The non-progression proportion is defined as the proportion of patients free of            progression 6 months after talazoparib start. Disease progression will be based on (i) tumor assessment made by the investigators according to the RECIST[…]

Read More »

The Protein Inhibitor Tazemetostat Could Soon Treat Mesothelioma

Mesothelioma could soon be treated by tazemetostat, a new protein inhibitor. Research groups at the American Society of Clinical Oncology made presentations speaking about the effectiveness of the drug on different cancers, with one of them being mesothelioma. It was shown to be effective, and could eventually be a second-line[…]

Read More »

A Combination of Immunotherapy Drugs Could Help Mesothelioma Patients

Mesothelioma is an incurable cancer of the mesothelium resulting from asbestos exposure. Many clinical trials have been found to help patients but there is still no cure. People primarily have pleural mesothelioma where the linings of the lungs have cancer, but it can also affect the lining of the abdomen[…]

Read More »

Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma

Primary Outcome Measures Local tumor infiltration by cytotoxic cluster of differentiation 8 positive (CD8+) cells [ Time Frame: After cryoablation of mesothelioma up to 1 year ] Will be tested by cryoablating a small region of tumor at the time of pleural biopsy. Preponderance of T cells in ablated tumor tissue in comparison to[…]

Read More »

Keytruda is Now Approved for Mesothelioma and Other Cancers

Keytruda is now approved for certain mesothelioma patients. The immunotherapy drug has been tested for mesothelioma before, but has not been approved for the treatment of it. The approval is for adult and pediatric cancers with unresectable disease and high mutational burden that have been treated and have no other[…]

Read More »

Halofuginone Could Soon be Used to Treat Mesothelioma

Mesothelioma is a devastating cancer that primarily affects the lining of the lungs and abdomen. Once exposed to asbestos, it can take years to develop and after being diagnosed, there are not many options for patients. Since there is not a cure, clinical trials can give people hope and can[…]

Read More »

177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours (LuPARP)

Primary Outcome Measures Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: up to 6 months after last treatment cycle ] To assess the number of participants with toxicity of 177Lu-DOTA-TATE in combination with olaparib measured by NCI Common Toxicity Criteria v 5.0 Secondary Outcome Measures TTP [ Time Frame: 3[…]

Read More »

Opdivo and Yervoy Work Together to Treat Pleural Mesothelioma

Mesothelioma is an aggressive cancer with very few treatment options. Patients have a low survival rate, but there is hope with clinical trials. If a clinical trial is found to be effective, patients could live longer and could eventually be cured. Opdivo and Yervoy are two immunotherapy drugs that are[…]

Read More »

DuRvalumab With Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma (DREAM3R)

Patients with malignant pleural mesothelioma (MPM) that cannot be surgically removed will receive first-line treatment with standard chemotherapy of pemetrexed and cisplatin. Two-thirds of the participants in the study will be randomly assigned to also receive a new treatment called durvalumab.

Read More »

Neoadjuvant Chemotherapy Does not Improve Survivability in Pleural Mesothelioma Patients

Neoadjuvant chemotherapy is typically used to shrink tumors before surgery to make it easier to remove them. It has been thought that the combination of drugs and surgery can help patients survive longer, but a study at Duke has found that it does not increase survival in pleural mesothelioma patients.[…]

Read More »